New River To Co-Promote ADHD Drug With Shire
This article was originally published in The Pink Sheet Daily
Executive Summary
New River said it will exercise its right to promote with Shire the ADHD treatment NRP104, currently pending at FDA. New River's co-promotion activities will commence in six months or upon the commercial launch of the amphetamine product